Hypothesis

Transient rapamycin treatment reprograms the lysosomal–autophagy axis in stem‑cell niches, creating an epigenetic memory that maintains heightened senescent‑cell clearance after the drug is withdrawn.

Mechanistic basis

• Rapamycin acutely inhibits mTORC1, which normally suppresses TFEB nuclear translocation and lysosomal biogenesis.[https://doi.org/10.1101/2023.10.26.564115]
• A short pulse allows TFEB to drive lysosomal gene expression without triggering the chronic immunosuppressive tone seen with continuous dosing.[https://www.jci.org/articles/view/67674]
• The resulting increase in autophagic flux clears damaged mitochondria and protein aggregates, reducing the SASP burden in neighboring cells.
• Concurrently, mTORC1 inhibition reduces histone acetylation at promoters of senescence‑associated genes via decreased acetyl‑CoA production, establishing a repressive chromatin state that persists after mTOR activity returns.[https://doi.org/10.7554/elife.16351.001]
• This dual action—enhanced clearance plus epigenetic silencing—creates a self‑reinforcing loop that keeps senescent cell numbers low even when mTOR signaling rebounds.

Testable predictions

1. In middle‑aged mice given an 8‑week rapamycin pulse, the fraction of p16^Ink4a^+ senescent cells in cardiac tissue and periodontal bone will remain significantly below baseline for at least 8 weeks after treatment stops, whereas continuously treated mice will show rebound once drug is withdrawn.
2. Genetic or pharmacologic inhibition of TFEB during the rapamycin pulse will abolish the long‑term reduction in senescent cells and the functional improvements (e.g., echocardiography‑derived diastolic parameters).
3. Chromatin immunoprecipitation for H3K27ac at Cdkn2a (p16) promoters will show reduced acetylation persisting after rapamycin withdrawal only in the transient‑pulse group.

Experimental design

• Groups (n=12 per group): (a) vehicle control, (b) continuous rapamycin (2 mg/kg/day) for 8 weeks, (c) transient rapamycin (same dose, 8 weeks then washout), (d) transient rapamycin + TFEB knockout (via LysM‑Cre;Tfeb^fl/fl) or TFEB inhibitor.
• Readouts taken at weeks 0, 8, and 16: senescence flow cytometry (p16^Ink4a^+), lysosomal activity (LysoTracker), cardiac echocardiography, micro‑CT of alveolar bone, SASP cytokine panel.
• Analysis: two‑way ANOVA with post‑hoc Tukey; persistence defined as no significant difference between week 8 and week 16 values in the transient group but a significant rise in the continuous group after washout.

Potential outcomes

• If predictions hold, the data will support a model where brief mTOR inhibition seeds a lysosomal‑epigenetic program that outlives the drug, reconciling the 'harder life' critique with observed tissue‑specific rejuvenation.
• If TFEB blockade erases the persistent benefit, it confirms lysosomal biogenesis as the critical mediator rather than generic metabolic suppression.
• Lack of epigenetic senescence‑gene repression would suggest that the lasting functional improvements arise solely from cleared senescent cells, prompting a search for other memory mechanisms.

Implications

Optimizing pulsed rapamycin regimens to harness this lysosomal‑epigenetic memory could extend healthspan while avoiding the immunosuppressive and metabolic costs of chronic mTOR inhibition, moving the field from mimicking scarcity toward actively resetting cellular aging programs.